Clarus Therapeutics Holdings Quick Ratio (CRXT) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Clarus Therapeutics Holdings Inc.  (NASDAQ: CRXT)

Clarus Therapeutics Holdings's Quick Ratio

CRXT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Clarus Therapeutics Holdings's Cash & cash equivalent grew by 109.84 % in the Q2 2022 sequentially, while Current Liabilities decreased, this led to improvement in Clarus Therapeutics Holdings's Quick Ratio to 0.31, above Clarus Therapeutics Holdings Inc. average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 192 other companies have achieved higher Quick Ratio than Clarus Therapeutics Holdings in second quarter 2022. While Quick Ratio total ranking has improved so far during the Q2 2022 to 4000, from total ranking in the first quarter 2022 at 4812.

Explain Quick Ratio?
How much Cash & cash equivalents CRXT´s has?
What are CRXT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRXT Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change 4521.01 % 1536.45 % -13.66 % - -
Y / Y Cash & cash equivalent Change 8438.98 % 2138.36 % 82.95 % - -
Quick Ratio MRQ 0.31 0.14 0.4 0.34 0.17
CRXT's Total Ranking # 4000 # 4812 # 3631 # 3871 # 3539
Seq. Current Liabilities Change -6.29 % -0.16 % 2.61 % 4713.61 % -66.81 %
Seq. Cash & cash equivalent Change 109.84 % -65.41 % 20.33 % 9677.09 % -44.99 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 193
Healthcare Sector # 1097
Overall Market # 4000


Quick Ratio Statistics
High Average Low
0.4 0.27 0.14
(Dec 31 2021)   (Mar 31 2022)




Financial Statements
Clarus Therapeutics Holdings's Current Liabilities $ 62 Millions Visit CRXT's Balance sheet
Clarus Therapeutics Holdings's Cash & cash equivalent $ 19 Millions Visit CRXT's Balance sheet
Source of CRXT's Sales Visit CRXT's Sales by Geography


Cumulative Clarus Therapeutics Holdings's Quick Ratio

CRXT's Quick Ratio for the trailling 12 Months

CRXT Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 215.35 % 145.51 % 77.5 % - -
Y / Y Cash & cash equivalent TTM Growth 408.79 % 288.85 % 239.39 % - -
Quick Ratio TTM 0.3 0.29 0.36 0.25 0.18
Total Ranking TTM # 5617 # 3673 # 3317 # 3696 # 0
Seq. Current Liabilities TTM Growth 30.58 % 45.6 % -7.15 % 78.63 % 1.66 %
Seq. Cash & cash equivalent TTM Growth 32.82 % 17.81 % 32.35 % 145.67 % 1.51 %

Quick ratio ranking by company, industry and sector >> Back to CRXT Financial Strength Comparisons >> Go to Compare CRXT Quick Ratio to its Competitors

On the trailing twelve months basis CRXT Cash & cash equivalent more than doubled by 8438.98 % in Q2 2022 year on year, faster than Current Liabilities, this led to increase in in Clarus Therapeutics Holdings's Quick Ratio to 0.3, above CRXT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 195 other companies have achieved higher Quick Ratio than Clarus Therapeutics Holdings. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 3673 to 5617.

Explain Quick Ratio?
How much Cash & cash equivalents CRXT´s has?
What are CRXT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 196
Healthcare Sector # 1212
Within the Market # 5617


trailing twelve months Quick Ratio Statistics
High Average Low
0.3 0.28 0.25
(Jun 30 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Tc Biopharm holdings Plc  0.81 $ 7.395  Millions$ 9.164  Millions
Greenlight Biosciences Holdings Pbc  0.80 $ 44.132  Millions$ 55.217  Millions
Cidara Therapeutics Inc   0.78 $ 24.637  Millions$ 31.455  Millions
Tevogen Bio Holdings Inc   0.72 $ 0.186  Millions$ 0.259  Millions
Allena Pharmaceuticals Inc.  0.66 $ 6.589  Millions$ 10.045  Millions
Novavax inc   0.64 $ 1,375.587  Millions$ 2,156.239  Millions
Fate Therapeutics Inc   0.60 $ 55.275  Millions$ 91.518  Millions
Redwoods Acquisition Corp  0.57 $ 0.447  Millions$ 0.780  Millions
Tradeup Acquisition Corp  0.57 $ 0.088  Millions$ 0.155  Millions
Amgen Inc   0.57 $ 7,183.000  Millions$ 12,618.000  Millions
Acorda Therapeutics Inc   0.56 $ 23.127  Millions$ 41.120  Millions
Atlantic Coastal Acquisition Corp Ii  0.51 $ 0.295  Millions$ 0.583  Millions
Elutia Inc   0.47 $ 16.489  Millions$ 34.749  Millions
Nkgen Biotech Inc   0.44 $ 1.260  Millions$ 2.856  Millions
Biogen Inc   0.43 $ 2,151.300  Millions$ 5,018.000  Millions
Protalix Biotherapeutics inc   0.40 $ 12.492  Millions$ 30.960  Millions
Galaxy Enterprises Inc   0.37 $ 2,594.000  Millions$ 7,073.000  Millions
Clarus Therapeutics Holdings Inc.  0.31 $ 19.173  Millions$ 61.806  Millions
Applied Genetic Technologies Corporation  0.27 $ 46.366  Millions$ 174.207  Millions
Replicel Life Sciences Inc   0.22 $ 0.352  Millions$ 1.588  Millions
Immunitybio inc   0.22 $ 82.938  Millions$ 376.050  Millions
Zura Bio Limited  0.21 $ 0.221  Millions$ 1.041  Millions
Scilex Holding Company  0.19 $ 0.351  Millions$ 1.830  Millions
Gilead Sciences Inc   0.16 $ 924.000  Millions$ 5,701.000  Millions

Date modified: 2026-09-08T15:10:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.